Prescient Therapeutics Limited

Informe acción ASX:PTX

Capitalización de mercado: AU$46.7m

Salud financiera de hoja de balance de Prescient Therapeutics

Salud financiera controles de criterios 6/6

Prescient Therapeutics tiene un patrimonio de los accionistas total de A$22.6M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$24.8M y A$2.2M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoAU$18.44m
PatrimonioAU$22.61m
Total pasivoAU$2.15m
Activos totalesAU$24.76m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

Mar 12
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth

We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Nov 14
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate

Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Aug 01
Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth

Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Nov 22
Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why

Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Jun 19
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

Feb 27
Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

Nov 05
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now

We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Aug 26
We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth

Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

May 08
Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans

Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Jan 11
Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$21.4M) de PTX superan a sus pasivos a corto plazo (A$2.1M).

Pasivo a largo plazo: Los activos a corto plazo de PTX (A$21.4M) superan a sus pasivos a largo plazo (A$66.4K).


Historial y análisis de deuda-patrimonio

Nivel de deuda: PTX está libre de deudas.

Reducción de la deuda: PTX no tenía deudas hace 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PTX tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: PTX dispone de suficiente cash runway para 1.8 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 16.6% cada año.


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target